With CAR T-cell therapy, similarly to traditional chemotherapy, the use of a single agent will not remain effective in treating a cancer, and thus multi-agent regimens are needed. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Nirali Shah, MD, of the National Cancer Institute, National Institutes of Health, Bethesda, MD, discusses an exciting upcoming clinical trial, which plans to combine anti-CD22 and anti-CD19 CAR T-cell therapies for patients with B-cell malignancies.
Bispecific CAR T-cell therapy: combining anti-CD19 and CD22 CAR T-cells
